GEN Exclusives

More »

GEN News Highlights

More »
Jun 20, 2007

SRI’s Oncology Candidate Wins Development Support from NCI

  • SRI International received support from the NCI thus gaining access to the drug development resources of the Developmental Therapeutics Program. The company will use these assets to further the preclinical development of its drug to treat advanced cancers. SR16388, a novel antiangiogenic drug, is being investigated for the treatment of multiple tumor types, including metastatic prostate cancer.

    "SR16388 is the third SRI drug candidate to be awarded development support from the National Cancer Institute," points out Nathan Collins, Ph.D., executive director of drug discovery in SRI's biosciences division.

    The contract was won through NCI’s Rapid Access to Intervention Development, a peer-reviewed competitive award program designed to assist translation of novel anticancer therapeutics to the clinic.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?